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ABSTRACT 
In previous study, the Vacll gene has been constructed through the 
technique of assembly PCR and has been cloned into pKK to produce surface 
display vaccine candidate (pTMSinakVacll). Vacll gene is a synthetic gene 
consists of selected T cell epitopes of Mycobacterium tuberculosis (MTB) genes 
namely ESAT6, MTP40, 38kD and MPT64. 
In this study, Vacll gene was cloned into pNMN013 for development of a 
recombinant BCG vaccine. PCR was used for the amplification of the gene DNA 
from pTMSinakVacll. The PCR products (Vacll gene) were visualized directly on 
agarose gel. The PCR product was first cloned into pTOPO vector. The PCR 
product were also digested with Nhel and Ndel and cloned into Nhel and Ndel 
digested pNMN013. The plasmids were transformed into E.coli. There were 
some colonies grown on the agar plate. 
Finally, the colonies were screened using PCR technique and restriction 
enzyme analysis. But after the screening procedures were done no expected 
recombinant plasmid were obtained. 
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INTRODUCTION 
The acid-fast bacillus Mycobacterium tuberculosis is the causative agent of 
tuberculosis (TB). Humans are the natural host for this pathogen, which is transmitted 
via the respiratory route. Tuberculosis is easily spread from one person to another 
person through the air by coughing, sneezing, laughing and even talking. The group 
that at high risk are health workers who work in long term care of the infected 
persons, intravenous drug users, people in close contact with infected active 
tuberculosis and in HIV/AIDS patients(Ramaswamy and Musser,1998). 
This bacteria can affect several organs includes lung, brain, kidney, bone and 
other organs. Strains of M.tuberculosis resistant to antimycobacterial agents are 
recovered from immunocompetent and immunocompromised patients' worldwide. 
This infection is the leading cause of mortality in adults due to an infectious agents 
and account for 26 percent of all preventable adult deaths globally (Ramaswamy and 
Musser, 1998). There are approximately 8 million new cases of tuberculosis worldwide 
and at least 1.5 million deaths per year. 
Increasing trends can also be seen in Malaysia. In the early 1940s and 1950s, 
tuberculosis (TB) was the number one cause of death in Malaysia. Patients with TB 
were admitted to the many sanatoria in various parts of the country and were often 
managed by surgical means. TB chemotherapy became available only in the late 
1950s. At this time, TB was already a major cause of morbidity and mortality. 
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Realizing its seriousness, the Malaysian government launched its National TB 
Control Programme (NTP) in 1961. At that time, the recommended treatment for TB 
was a combination of three drugs, namely, streptomycin, isoniazid and 
paraaminosalicylic acid (PAS) given for 2 months followed by isoniazid and PAS 
given for 12 months. Generally the treatment used to last 1-2 years (Kupusamy, 
2004). 
Over the past 1 0 years there has been a steady increase in the number of TB 
notifications. In the year 2000, a total of 15,057 cases of all forms ofTB were notified. 
The incidence rate per 100,000 populations is 64.7. Of these 8154 were smear 
positive. The incidence of smear positive cases is 34.7 per 100,000 populations. The 
state with the highest disease burden is Sabah followed by Wilayah Persekutuan, 
Sarawak and Pulau Pinang, respectively (Kuppusamy, 2004). 
TB will undoubtedly increase in prevalence in most countries due to the human 
immunodeficiency virus (HIV) pandemic. In alarming statistics and trends, the World 
Health Organization declared TB to be a global public health emergency. The US 
centers for Disease Control and Prevention national surveillance system recorded 93 
449 TB cases from 1993 through 1996, including 1457 cases of multidrug resistant 
TB (MDR-TB) (Ramaswamy and Muasser, 1998). 
Vaccines against tuberculosis (TB) provide one of the earliest examples of 
human immunoprophylaxis, since tuberculin was used by Koch over 100 years ago, 
for treating tuberculosis in humans infected with Mycobacterium tuberculosis. 
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The introduction of BCG, the attenuated strain of Mycobacterium bovis, by Calmette 
and Guerin in 1921, represents the earliest use of a live attenuated vaccine in human 
medicine (Griffin eta/., 2001). 
BCG is the most widely used and safest attenuated human vaccine, with more 
than 1 billion doses used worldwide in the past 80 years. Whereas BCG vaccination 
has been widely accepted and used in many countries for more than 50 years, 
controversy concerning its efficacy has emerged, since a systematic evaluation of 
BCG was carried out by WHO in Chingleput, South India, in the 1970s (Griffin et a/., 
2001). 
Results from this study showed that children vaccinated with BCG produced 
no discemable protection against TB, compared with non-vaccinated controls. 
Overall results from individual trials of human BCG vaccination carried out worldwide 
have shown highly variable levels of protection. The only consistent observation has 
been that BCG provides significant protection against bacteremic spread of 
tuberculosis and TB meningitis in children (Griffin eta/., 2001). 
A number of reasons have been advanced to explain the variations seen in the 
levels of protection obtained with BCG. These include prior TB infection or exposure 
to host immunocompetence, associated with malnutrition and environmental 
stressors and differing levels of ability and immunogenicity of strains of BCG might 
also have contributed to the inconsistent results. Vaccine may failure also have been 
due to the way in which the vaccine has been used, rather than due to any deficiency 
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in the vaccine (Griffin eta/., 2001). 
Therefore, development of an effective vaccine against tuberculosis is a big 
task. There are a many approaches in development TB vaccines. The current 
vaccine, BCG, is live attenuated mycobacteria. Attenuated vaccine is a live microbe 
but is weakened so that is mimicry an actual infection without causing actual disease. 
Live vaccines may give long term effectiveness because attenuated microbe replicate 
in body. But this vaccine is not recommended for people whose immune response is 
compromised because it will cause actual disease. 
One type of new vaccine being developed is the subunit vaccine consisting of 
proteins or peptides. Subunit vaccines have the ability to enhance immune 
responses and increases the duration of protection. However, these non-living 
subunit proteins have still failed to provide better protection than BCG. Furthermore, 
the subunit proteins are very expensive to produce and require multiple boosters 
(Norazmi and Mustaffa, 2002). 
Another approach in development of vaccine is recombinant BCG. BCG is re-
engineered to enhance its efficacy through inserting genes encoding 
immunodominant antigens or immunostimulatory genes. Some genes in BCG which 
has been deleted during the attenuation process may re-introduce and re-expressed 
in the recombinant BCG. The vaccine also would share the safety and low side 
effects of BCG. Furthermore, it should be inexpensive and easy to mass produce 
because costly purification and synthesis are not required. It is also noteworthy that 
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BCG vaccination could protect against leprosy. So, this approach needs to explore 
for the development of an effective vaccine against TB (Norazmi and Mustaffa, 
2002). 
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REVIEW OF LITERATURE 
The doubtful efficacy of bacille Calmette-Guerin (BCG) immunization against 
tuberculosis and the spread of the dual epidemic of human immunodeficiency virus 
(HIV) and tuberculosis has created a renewed global interest in developing improved 
preventive therapeutic reagent and diagnostic assays against tuberculosis. 
Furthermore, progressive innovations of molecular biology techniques and quite 
comprehensive information of Mycobacterium tuberculosis also encourage 
development of new vaccine (Prabhakar et a/., 1998). 
There are a current trends are seen in developing of vaccination, the first 
approach involves modifying BCG itself. BCG was developed through passaging a 
virulent strain of M.bovis over a period of almost 11 years. The second approach 
involves the use of subunit proteins and the more recent format of DNA vaccines. 
DNA vaccines involve cloning of antigen encoding genes into plasmid construds that 
can be expressed in mammalian cells. The DNA vaccines generally induce effective 
Th1 cellular responses, which are important for protection in tuberculosis (Zodpey et 
a/., 1999). 
Morris et at., (2000) documented that a single DNA vaccine encoding both the 
MPT -63 and MPT -83 tuberculosis antigens evoked partial protection against an 
aerogenic challenge with M.tuberculosis Erdman in the mouse model of pulmonary 
tuberculosis. Further he showed that immunization with a multivalent combination 
DNA vaccine containing the ESAT -6, MPT -64, MPT -63 and KatG constructs elicited 
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a strong protective response relative to the protection evoked by conventional BCG 
vaccine. 
DNA vaccine involves direct injection of plasmid DNA encoding specific antigens 
that can led to protective immunity (Davis eta/., 1993; Donnelly et al., 1994;Cohen 
and Steinman, 1997). 
According to Murray eta/., (1996) and Wangoo eta/., (2000), recombinant BCG 
expressing various cytokines such as interleukin-2, interferon gamma, or 
granulocyte-macrophage colony-stimulating factor have been shown to improve the 
response against M. tuberculosis antigens 
Recombinant BCG expressing listeriolysin of Listeria monocytogenes showed an 
enhanced capacity to stimulate CDS+ T cells according to Hess et a/., (1998). 
Horwitz eta/., (2000) reported that better protective efficacy of a recombinant BCG 
expressing an epitope of M.tuberculosis compared to the parent stain. Recombinant 
BCG that over expresses the 30 kDa Ag85 protein has been reported to provide 
better protection than BCG (Horwitz et a/., 2000). Hetzel et a/., (2000) have 
constructed recombinant mycobacteria by inserting specific foreign epitopes into the 
superoxide dismutase gene of the host. 
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Lacuna in literature 
Since BCG vaccine is not reliable, new vaccine against tuberculosis is urgently 
needed. Recombinant BCG approach for the development TB vaccine could be 
explored. 
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OBJECTIVE OF THE STUDY 
The aim of this research project is to clone Vacll, a synthetic multi-epitope, multi-
gene of Mycobacterium tuberculosis into pNMN013 for development of a 
recombinant BCG vaccine against tuberculosis. 
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MATERIALS AND METHODS 
MATERIALS 
Plasm ids 
Plasmid pTMSinakvacll as shown in Figure 1, containing the Vacll gene was 
obtained from Mohamed Sarhan, a PhD student of Associate Professor Dr. Mustaffa 
Musa, Department of Immunology, School of Medical Sciences, USM. Plasmid 
pNMN013 was obtained from research group Professor Dr. Norazmi Mohd. Nor. The 
map of pNMN013 is shown in Figure 2. 
Primers 
Primers were obtained from MWG Biotech (Germany). The sequences of primers 
used in this research project are: 
Vac11Nhe1 (Forward) CTCTGCTAGCATGACAGAGCAGCAG 
VaciiNDE1 (Reverse) CTATCATATGTTAATGATGGTGGTG 
Bacterial strain 
E.coli host strain TOP10 was obtained from the culture collection of the Molecular 
biology research laboratory, School of Medical Sciences, USM. 
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Ampicillin stock solution 50mglml 
500mg of Ampicillin powder was dissolved in 1Om I sterile dH20 and sterilized by 
filtration. The solution was aliquoted into sterile tubes and kept in 4°C. 
Kanamycin stock solution 100mglml 
1 OOOmg of Kanamycin powder was dissolved in 1Om I sterile dH20 and sterilized by 
filtration. The solution was aliquoted into sterile tubes and kept in 4°C. 
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Media 
Luria- Betani Broth and Agar 
Tryptone 
Yeast extracts 
5.0g 
2.5g 
5.0g 
500ml 
All ingredients were dissolved in 500ml dH20 and mixed thoroughly using a 
magnetic bar. The mixture then adjusted to increase pH 7.2 using NaOH. After that, 
the mixture was autoclaved at 121 oc in 15 minutes and aliquoted into sterile 
universal tubes. To make LB broth Ampicillin (50tJg/ml), the broth is cooled to sooc 
before adding SOOJJI of the stock Ampicillin solution (50mg/mi).To make broth contain 
Kanamycin (501Jg/ml), the broth is adding with 2501JI of the stock Kanamycin solution 
( 1 OOmg/ml). 
To make LB agar, all ingredients are the same as the LB broth but 7. 5g 
bacteriological agar was added to a final concentration. The mixture was autoclaved 
at 121 oc in 15 minutes and cooled to 50°C.After that, antibiotic whether Ampicillin or 
Kanamycin was added to the mixture before pouring out into sterile petri dishes. 
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10X stock solution of Tris-Borate (TBE) buffer 
Tris- base 1 08g 
Boric acid 55g 
O.SM EDTA pH 8.0 40ml 
Or disodium EDT A. H20 9.3g 
All ingredients were mixed together and autoclaved at 121°C for 15 minutes. To 
prepare 1000ml of 0.5X TBE buffer, 50ml 10X stock solution will be diluted with 
950ml dH20. 
Loading buffer 
Glycerol (BDH chemicals) 3ml 
Bromophenol Blue (Sigma, USA) 0.03g 
The ingredients were mixed together with deionized distilled water (ddH20) to the 
final volume of 1Om I. The mixture was kept in a bottle covered with aluminium and 
was kept at 4 oc. 
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Ethidium bromide (EtBr2) solution (10mg/ml) 
1 g ethidium Bromide (Sigma, USA) was diluted with 1 0 ml ddH20 and mixed until 
completely dissolved. Then, the mixture was kept in dark bottle. 
A Hindlll marker (50pglpl) 
A Hindlll 0.5mg/t..tl 101JI 
Loading Buffer 801JI 
1X Tris-EDTA 101JI 
All ingredients were mixed and kept at 4°C. 
100bp Ladder (100pg/pl) 
100bp DNA ladder (0.5mg/ml) 20J..d 
Loading buffer 201JI 
1 X Tris .. EDTA 60fJI 
All ingredients were mixed together and kept at 4°C. 
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0.203g Of MgCI2.6H20 was dissolved in 100ml of sterile distilled water. The 
MgCI2.6H20 solution was poured in one bottle and then autoclaved at 121°C for 15 
minutes. After that, the bottle was allowed to cool and finally was kept at -20°C. 
1.4702g Of CaCI2.2H20 was dissolved in 100ml of sterile distilled water. The 
CaCI2.2H20 solution was poured in one bottle and then autoclaved at 121°C for 15 
minutes. After that, the bottle was allowed to cool and finally was kept at -20°C 
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METHODS 
Agarose Gel Electrophoresis 
Preparation of 0.8% Agarose Gel 
0.24g of LE agarose (Promega) was mixed with 30ml of O.SX TBE buffer and was 
heated in a microwave oven for approximately 2 minutes or until all ingredients were 
completely dissolved. The mixtures were then cooled using running tap water. After 
that, 0.5 ~I of 1 Omg/ml ethidium bromide was added. The solution was poured into a 
casting tray that assembled with comb. The gel was left about 15 minutes to let gel 
cold and firm. 
Running Agarose Gel Electrophoresis 
The solidified gel was placed into the running tank. 0.5X TBE was placed into the 
tank until the gel was flooded. Then, 1 0 IJI of each samples are mixed with 2 IJI of 
loading buffer and then placed into each well. After that, 1 IJI of 100bp marker and A 
Hindlll marker were loaded into another well. Electrophoresis was run at SOV for one 
hour. The DNA in gel was visualized using an image analyzer. 
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Calculation of Annealing Temperature 
Annealing temperature was calculated using the formula below: 
Melting temperature (Tm) = 2(A + T) + 4 (C + G) 
Annealing Temperature =Tm - soc (range 2-SOC) 
Vaci1Nhe1 (Fotward primer) 5' CTCTGCTAGCATGACAGAGCAGCAG 3' 
A=6, T=1, C=3, G=5 Tm= 2(6+1) + 4(3+5) 
Annealing Temperature =46°C -soc 
VaciiNDE1 (Reverse primer) 5' CTATCATATGTTAATGATGGTGGTG 3' 
A=3, T=6, C=O, G=6 Tm= 2(3+6) + 4(0+6) 
Annealing Temperature 
=42°C 
=42°C- soc 
=37°C 
Nhe1 and Nde1 sites are not include for annealing temperature calculation because 
these region do not bind to the template DNA. 
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PCR Reaction 
Reagents: 
MPOR Buffer 1-Buffer 6 
Forward primer(10 (Jm) 
Reverse primer(1 0 J,Jm) 
GC Normalizer 
DMSO 
dNTPs (3. 125mM) 
Taq Pfu polymerase 
DNA 
Total 
25.0 J.JI 
5.0 J.ll 
1.0 tJI 
1.0 Jjl 
10.0J,JI 
2.5JJI 
4.01JI 
1.01JI 
1.0JJI 
Polymerase chain reaction (PCR) was performed with Taq deoxyribonucleic 
acid (DNA) polymerase according to the manufacturer's instructions (MBI 
Fennentas). 
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The PCR reactions was subjected to initial denaturation at 95°C for 1 minute, 
30 cycles each of 30 seconds at 95°C, 30 seconds at 59°C, and 30 seconds at 72°C 
followed by final extension at 72°C for 30 minutes. The PCR products were analyzed 
on a 0.8% agarose gel and stained with ethidium bromide. 
Gel Purification 
Impure PCR products are caused by smearing and multiple banding. Therefore, 
purification was needed in order to obtain pure product. The purification of gel was 
done using QIAquick Gel Extraction Kit. Up to 400mg agarose can be processed per 
spin column. 
The DNA fragment visualized under UV and the band excised from the 
agarose gel with a clean and sharp scalpel. The size of each gel slice was minimized 
by removing extra agarose because gel purification will result in a dilution of PCR 
product. 
The gel slices were weighed in colorless tubes. 3 volumes of Buffer QG were 
added to 1 volume of gel (100mg-100 IJI).Tubes were incubated at sooc for 10 
minutes or until the gel slice were completely dissolved. After the gel slices had 
dissolved completely, the color of the mixture was checked yellow. The adsorption of 
DNA to the QIAquick membrane is efficient only at pH< 7.5.Buffer QG contains a pH 
indicator which is yellow at pH< 7.5, allowing easy determination of the optimal pH for 
DNA binding. 
22 
The dissolved gel is applied to the QIAquick column and centrifuged for 1 
minute at 24°C at 13 000 rpm. Flow-through discarded and the QIAquick column was 
placed back in the same collection tube. SOOJJI of QG buffer was added into column 
then spun again. This step will remove all traces of agarose. 
7501JI of PE buffer was added to QIAquick column and centrifuged for 1 
. 
minute. The Flow-through was discarded and QIAquick column was centrifuged for 
an additional minute at 13 000 rpm. The residual ethanol from PE buffer will not be 
completely removed unless the flow through is discarded before this additional 
centrifugation. 
QIAquick column was placed into a clean 1. Sml microcentrifuge tube. To elute 
DNA, 501JI of EB buffer (10mM Tris-CI, pH8.5) added to the center of the QIAquick 
membrane and centrifuged for 1 minute. Elution efficiency is dependent on pH. The 
maximum elution efficiency is achieved between pH 7.0 and 8.5. 
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Cloning into TOPO 
To ensure that most of the PCR product has an A overhang, an A-Tailing procedure 
was carried out as follows: 
DNA (purified product) 
1 OX PCR buffer with MgS04 
pfu DNA polymerase 
dATP (10mM) 
Total 
10 .O~o.d 
1.0 IJI 
0.75 ~I 
0.50 IJI 
12.25 IJI 
All the solutions were mixed together and briefly spun then, incubated at 72°C for 30 
minutes. Cloning into TOPO was performed according to the manufacturer's 
instructions (Invitrogen). 
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